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Vinﬂunine, the most recent Vinca alkaloid in clinical development, demonstrated superior antitumour activity to other Vincas in
preclinical tumour models. This study aimed to deﬁne its molecular mechanisms of cell killing in both parental sensitive and
vinﬂunine-resistant P388 leukaemia cells. Vinﬂunine treatment of these cells resulted in apoptosis characterized by DNA
fragmentation and proteolytic cleavage of poly-(ADP-ribose) polymerase. Apoptosis-inducing concentrations of vinﬂunine
caused c-Jun N-terminal kinase 1 stimulation, as well as caspases-3/7 activation. This activation of caspases and the induction of
apoptosis could be inhibited by the caspase inhibitor acetyl-Asp-Glu-Val-Asp-aldehyde. Interestingly, the apoptosis signal
triggered by vinﬂunine in these P388 cells was not mediated through Bcl-2 phosphorylation. In addition, when vinﬂunine
resistance was developed in P388 cells, it was associated with resistance to vinﬂunine-induced apoptosis, as reﬂected by a loss
of capacity to induce DNA fragmentation and PARP degradation, and characterized by increased levels of Bcl-2 and Bﬂ-1/A1.
Therefore, these data indirectly implicate Bcl-2 and Bﬂ-1/A1 in vinﬂunine-induced cell death mechanisms.
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Vinﬂunine or 20',2 0 '-diﬂuoro-3',4'-dihydrovinorelbine, is a novel
Vinca alkaloid selectively ﬂuorinated by superacid chemistry in a
rarely exploited region of the velbanamine moiety (Fahy et al,
1997). It was selected for clinical development on account of its
markedly superior antitumour efﬁcacy in vivo in preclinical studies,
in a series of experimental models compared to other Vinca alka-
loids (Kruczynski et al, 1998a; Hill et al, 1999). Promising results
have recently been obtained in Phase I clinical trials, now
completed in Europe with three partial responses being identiﬁed
in patients with advanced breast cancer or renal cell carcinoma
(Fumoleau et al, 2000). Phase II clinical evaluations in melanoma
and renal carcinoma are now on going.
In vitro studies have conﬁrmed its mitotic-arresting and tubulin-
interacting properties (Kruczynski et al, 1998b) and identiﬁed
differences in tubulin binding relative to the other Vincas (Kruc-
zynski et al, 1998b; Lobert et al, 1998). However, the molecular
mechanisms of cell killing by vinﬂunine remain to be characterized.
Anticancer agents are known to trigger apoptotic mechanisms in
tumour cells, especially those of haematological origin, although
the relative contribution of apoptosis to drug-induced cell death
in advanced solid tumours remains controversial (Brown and
Wouters, 1999).
Apoptosis, a genetically regulated process triggered by various
biological signals, can be transduced through numerous pathways
(Wang et al, 1999b). However, cells which die by apoptosis exhibit
typical morphological changes, DNA fragmentation (Wyllie, 1997)
and activate a cascade of aspartate-speciﬁc cysteine proteases, namely
the caspases. Caspase activity is responsible, either directly or indir-
ectly, for the cleavage of cellular proteins which are
characteristically proteolysed during apoptosis (Miller, 1997). For
example, once activated, caspase-3 cleaves speciﬁc substrates includ-
ing the nuclear protein poly(ADP-ribose) polymerase (PARP),
involved in DNA repair and genome maintenance (Kaufmann et al,
1993). Microtubule targeting agents, including taxanes and Vinca
alkaloids, have been shown to promote apoptosis in cancer cells
through a complex process involving many protein kinase signalling
pathways (Wang et al, 1999b), including activation of c-Jun N-term-
inal kinases (JNKs) (Stone and Chambers, 2000). Furthermore, a
critical role for the Bcl-2 protein family in cell death induced by
microtubuledamaging agentshasbeensuggested(Wangetal,1999b).
The aim of this study was to determine whether vinﬂunine-
induced cell death in murine P388 leukaemia cells exhibited
biochemical characteristics of apoptosis. The contributions of
JNK1 signalling, caspases and of Bcl-2 protein family members to
vinﬂunine-induced cell death were also investigated. Furthermore,
we examined whether vinﬂunine resistance developed in vivo in
P388 cells (P388/VFL) was associated with changes in vinﬂunine-
activated programmed cell death.
MATERIALS AND METHODS
Cells
Murine sensitive P388 (National Cancer Institute, Tumour Reposi-
tory, Frederick, MD, USA) and the in vivo established vinﬂunine-
resistant P388/VFL (Etie ￿vant et al, 1998) leukaemia cells were
collected from the peritoneal cavities of DBA/2 mice (DBA/2JIco,
Iffa Credo, L’Arbresle, France), where they were maintained in vivo,
and adapted to in vitro culture conditions in RPMI 1640 medium
supplemented with 10% heat-inactivated horse serum, 4 mM L-
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71 fungizone, 100 mgm l
71 penicillin-strep-
tomycin, and 20 mM b-mercaptoethanol. The vinﬂunine-resistant
P388/VFL cells established in vivo initially were subsequently char-
acterized in vitro as showing a 17-fold level of resistance to
vinﬂunine, with marked overexpression of P-glycoprotein (P-gp)
associated with reduced accumulation of [
3H]-vinﬂunine (Etie ￿vant
et al, 1998).
Nuclear staining and apoptotic cell percentage
determination
After 24 h of treatment with vinﬂunine, P388 cells collected by
centrifugation were ﬁxed with methanol:acetic acid (3:1) for
30 min prior to staining using a Diff-Quik kit (Maurepas, France),
based on the Giemsa-May-Gru ¨nwald technique, before examina-
tion under light microscopy. At least 300 cells were scored for
the incidence of apoptosis, in ﬁve randomly selected ﬁelds and
the per cent of apoptotic cells with fragmented nuclei and
condensed chromatin relative to the total was calculated.
DNA fragmentation assay
DNA fragmentation was quantitated according to Bertrand et al
(1991). Brieﬂy,
14C-prelabelled thymidine cells, after exposure to
vinﬂunine, were pelleted and lysed for 30 min at 48Ci n1 m l
ice-cold PBS buffer containing 0.5% (v v
71) Triton-X-100 and
20 mM EDTA, pH 8. Cellular lysates were centrifuged at 12000 g
for 30 min at 48C to separate low molecular weight DNA frag-
ments (supernatant) from intact chromatin or high molecular
weight DNA (pellet). Radioactivity was measured in each collected
fraction and the amount of fragmented [
14C]DNA released into the
supernatant was expressed as a percentage of the total. Results are
expressed as the drug-speciﬁc percentage of DNA fragmented using
the formula:(F–F0/100–F0)6100, where F and F0 represent
percentages of DNA fragmentation in drug-treated and control
cells, respectively.
Determination of caspase activation in cellular extracts
After in vitro vinﬂunine treatment for 24 h, P388 cells were
washed with ice-cold PBS and then lysed for 10 min on ice with
50 mM HEPES, pH 7.4, 0.1% Chaps, 1 mM DTT and 0.1 mM
EDTA. Caspase activity in the supernatant (100 ml) was deter-
mined using the caspases-3/7 speciﬁc colorimetric substrate,
acetyl-Asp-Glu-Val-Asp-p-nitroaniline (Ac-DEVD-p-NA) (Biomol,
Plymouth, USA). Brieﬂy, 20 mg protein extract were incubated
with 200 mM substrate peptide in 50 mM HEPES, pH 7.4,
100 mM NaCl, 0.1% Chaps, 10 mM DTT, 1 mM EDTA and 10%
glycerol. When using the caspases-3/7 inhibitor, Ac-DEVD-CHO
(Biomol), cell free extracts were incubated with the inhibitor
(200 mM ﬁnal) for 10 min at 378C prior to substrate addition.
Production of cleaved p-nitroaniline from the tetrapeptide
substrate Ac-DEVD-p-NA was monitored using a Dynatech
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Figure 1 Vinﬂunine-induced DNA fragmentation in P388 cells.
14C-pre-
labelled thymidine P388 cells were exposed either to 0.1–0.5 mM vinﬂu-
nine for 24 h (A) or to 0.3 mM vinﬂunine for 3 to 24 h (B). Vinﬂunine-
induced fragmented DNA was measured using the intact chromatin preci-
pitation assay, as described in Materials and methods. Results are expressed
as means from triplicates, with the associated standard error of the esti-
mate of the mean value (s.e.m.).
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Figure 2 Induction of JNK1 activation by vinﬂunine in P388 cells. P388
cells were treated with 0.025 to 0.5 mM vinﬂunine for 6 h. JNK1 activity
was determined in cell lysates by immunocomplex assay, as described in
Materials and methods. Results, from two independent experiments, are
expressed as average increase of JNK1 activity relative to the controls+
s.e.m. Statistical evaluation using the Student t-test showed that the values
for 0.25 and 0.5 mM were signiﬁcant, with respective P values of 0.015 and
50.001.
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quantiﬁcation of the total DEVD-speciﬁc protease activity. Assays
were performed in triplicate and results presented as average
absorbance+s.e.m.
Determination of JNK activation in cell extracts
JNK activity was determined by an immunoprecipitation assay
(Wang et al, 1998). After in vitro vinﬂunine treatment, P388 cells
were washed in PBS and lysed for 10 min on ice with 50 mM
Tris-HCl, pH 7.5, 150 mM NaCl, 1% NP40, 5 mM NaF, 1 mM
sodium orthovanadate. After centrifugation, the cellular extract
(supernatant, 1 mg protein) was mixed with 20 ml anti-JNK1 anti-
body coupled to agarose (Santa Cruz Biotechnology, Santa Cruz,
CA, USA) and incubated overnight. The immunocomplex was
recovered by sedimentation for 5 min at 20000 g, washed three
times with JNK reaction buffer containing 25 mM HEPES,
pH 7.5, 25 mM MgCl2,2 5 m M b-glycerophosphate, and 0.1 mM
sodium orthovanadate. The immunoprecipitate was resuspended
in 50 ml JNK reaction buffer supplemented with 10 mM ATP,
5 mCi of
33P-ATP (2500 Ci mmol
71; Amersham, Les Ulis, France)
and 0.5 mg GST-c-Jun substrate (amino acids 1–79)-agarose
(Santa Cruz Biotechnology) and incubated for 30 min at 308C.
Samples were analyzed by spotting an aliquot of the reaction
mixture onto a P81 phosphocellulose membrane (Whatman,
Maidstone, UK) which was allowed to dry and then washed three
times in 1% (v v
71) phosphoric acid in 50% (v v
71) ethanol.
Radioactivity associated with c-Jun was assessed by scintillation
counting. Assays were performed in duplicate, on at least three
separate occasions, and results are expressed relative to the activity
of controls.
Western blot analyses
Following in vitro treatment with vinﬂunine, whole cell extracts
were subjected to SDS–PAGE before transfer onto nitrocellulose
membranes. After blocking non-speciﬁc sites, this was probed
overnight with an anti-PARP (Serotec, Oxford, UK), an anti-
Bcl-2 (Interchim, Montluc ¸on, France), an anti-Bcl-xL (Tebu, Le
Perray-en-Yvelines, France), an anti-Bﬂ-1/A1 (Tebu, Le Perray-
en-Yvelines, France), or an anti-Bax antibody (Euromedex, Souf-
felweyersheim, France), followed by a 1-h incubation with
appropriate secondary antibody conjugated to peroxidase (Jackson
Immunoresearch Labs, West Grove, PA, USA). When the b-actin
loading control was included, probing with an anti-b-actin (Tebu,
Le Perray-en-Yvelines, France) or an anti-Bcl-2 family protein
antibody was carried out separately. Proteins of interest were
visualised by enhanced chemoluminescence (Pierce, Rockford, Il,
USA) and quantiﬁed using a Bio-Rad (Ivry-sur-Seine, France)
MolecularImager.
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Figure 3 Effects of vinﬂunine on caspases 3/7 activity and PARP cleavage. (A) Enzymatic Ac-DEVD-p-NA cleavage activity in P388 leukaemia cell extracts
following a 24-h incubation with vinﬂunine. Twenty mg protein from cell extracts prepared from cells exposed to 0 (~), 0.05 (&), 0.15 (^), 0.3 (*) mM
vinﬂunine for 24 h were assayed for caspases-3/7 dependent activity using the synthetic substrate Ac-DEVD-p-NA. Caspases-3/7 activity was also evaluated
in presence of 200 mM Ac-DEVD-CHO, the caspases-3/7 inhibitor (m), for the cell extracts treated with 0.3 mM vinﬂunine. Assays were performed in tri-
plicates and results were expressed as average optical density values+s.e.m. (B) Cleavage of PARP after either a 24 h-incubation of P388 cells with 0.1–
0.5 mM vinﬂunine (B1) or a 3–24-h incubation with 0.3 mM vinﬂunine (B2). Vinﬂunine-induced PARP cleavage was analyzed by Western blot. Results are
expressed as means from 2–3 independent experiments of the percentage of degraded form vs total (degraded plus native) PARP forms+s.e.m.
Vinflunine-induced apoptosis in leukaemic cells
A Kruczynski et al
145
ã 2002 The Cancer Research Campaign British Journal of Cancer (2002) 86(1), 143–150RESULTS
Does vinﬂunine induce apoptosis in P388 leukaemia
parental cells?
Vinﬂunine-induced DNA fragmentation Initially, the chroma-
tin precipitation assay was used to assess the cell death response of
P388 leukaemia cells to vinﬂunine treatment. Vinﬂunine induced
fragmentation in P388 cells in a dose- (Figure 1A) and time-
(Figure 1B) dependent manner. DNA fragmentation became appar-
ent following 24 h continuous exposure to 0.1–0.5 mM vinﬂunine
(Figure 1A) and was detectable as early as 3 h with 0.3 mM vinﬂu-
nine (Figure 1B). Vinﬂunine-induced DNA fragmentation was also
observed using the Tunel assay (data not shown).
Vinﬂunine-activated JNK1 A 6-h treatment with 0.025, 0.25 or
0.5 mM vinﬂunine resulted in the activation of JNK1 in these P388
cells in a dose-dependent manner, as illustrated in Figure 2.
Vinﬂunine-stimulated caspase protease activities and
caused PARP degradation
Vinﬂunine, over a concentration range of 0.05–0.3 mM, stimulated
caspases-3/7 activities in P388 cells, in a dose-dependent manner
(Figure 3A). The inhibitor, Ac-DEVD-CHO was able to inhibit
vinﬂunine-induced DEVD-speciﬁc protease activation, conﬁrming
that caspases-3/7 were speciﬁcally activated by vinﬂunine (Figure
3A). Their activation is known to lead to the cleavage of several
proteins, with PARP (116-kD) being cleaved to produce an 85-
kD fragment during apoptosis (Kaufmann et al, 1993). As shown
in Figure 3B, PARP and its 85-kD cleaved fragment were detected
in P388 cells by immunoblotting, following incubation with vinﬂu-
nine. A dose-, as well as a time-dependent, cleavage of PARP was
observed, with up to 59% PARP cleavage product being recorded
after a 24-h exposure to 0.5 mM vinﬂunine (Figure 3B1), and this
was detected as early as 3 h with 0.3 mM vinﬂunine (Figure 3B2).
Overall these results suggest that at least caspases-3/7 play a role
in the apoptotic signalling pathway induced by vinﬂunine in
P388 leukaemia cells.
Inhibition of vinﬂunine-induced apoptosis by
Ac-DEVD-CHO
The caspases 3/7 inhibitor Ac-DEVD-CHO inhibited vinﬂunine-
induced apoptosis, as demonstrated by a determination of apopto-
tic cell number. Optimal inhibition of 86% was noted at a
concentration of 300 mM (Figure 4). These results also provide
evidence that at least caspases-3/7 mediate vinﬂunine-induced
apoptosis in P388 cells.
Effects of vinﬂunine on Bcl-2 phosphorylation
Neither vinﬂunine (0.1–0.5 mM) nor taxol (0.04 and 0.4 mM), at
equi-cytotoxic concentrations, induced any alteration of the Bcl-
2 electrophoretic pattern in P388 cells after a 24-h exposure
(Figure 5A). Taxol was included as a reference since it has been
shown to induce Bcl-2 phosphorylation in human leukaemias
and solid tumour cells (Haldar et al, 1997). Furthermore, a
time-course study including treatment of these P388 cells with
0.3 mM vinﬂunine for 3 h to 48 h also failed to result in any
modiﬁcation of Bcl-2 status. A similar study was then conducted
with another cell type, namely human CEM leukaemia cells. After
a 24-h exposure to either vinﬂunine or taxol, immunoblot
analyses revealed a dose-dependent modiﬁcation of the Bcl-2 elec-
trophoretic pattern in these CEM cells, characterized by the
appearance of a slower mobility form of Bcl-2 (Figure 5B), similar
to that reported after serine-phosphorylation of Bcl-2 (Haldar et
al, 1995). These ﬁndings indicate therefore that microtubule
damaging agent-induced Bcl-2 phosphorylation appeared related
to the cell type studied.
Is vinﬂunine-induced resistance associated with changes in
vinﬂunine-activated programmed cell death or with
changes of apoptosis-related protein status?
PARP degradation and DNA fragmentation in P388/VFL
resistant cells In order to detect PARP cleavage and DNA frag-
mentation after a 24-h exposure of P388/VFL resistant cells to
vinﬂunine, it was necessary to increase the vinﬂunine concentra-
tions 10-fold (i.e., 2–5 mM) relative to those required to induce
comparable effects in the sensitive cells (Figure 6A,B). Therefore,
these P388/VFL resistant cells exhibited a 10-fold level of resistance
to vinﬂunine-induced apoptosis, consistent with their 17-fold level
of resistance to vinﬂunine-induced cytotoxicity.
Status of Bcl-2, Bcl-xL, Bﬂ-1/A1 and Bax proteins in P388
sensitive and P388/VFL resistant cells Western blot analyses
were performed to determine whether vinﬂunine resistance in
P388 leukaemia cells was associated with changes in relative endo-
genous Bcl-2, Bﬂ-1/A1, Bax, and Bcl-xL expression. As shown in
Figure 7, the basal level of expression of Bcl-2 was 3.7-fold increased
in P388/VFL resistant cells relative to the sensitive cells. In addition,
a 1.9-fold increase was detected in the basal level of Bﬂ-1/A1,
another anti-apoptotic protein in these resistant cells relative to their
sensitive counterparts (Figure 7). The pro-apoptotic protein Bax
and the anti-apoptotic protein Bcl-xL however were not differen-
tially expressed in sensitive and resistant cells (Figure 7).
DISCUSSION
This study aimed to identify the cell killing mechanisms of vinﬂu-
nine, selected for clinical development on account of its marked in
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British Journal of Cancer (2002) 86(1), 143–150 ã 2002 The Cancer Research Campaignvivo antitumour activity and good overall tolerance in preclinical
models (Kruczynski et al, 1998a; Hill et al, 1999) and its quantita-
tively distinct tubulin interacting properties, compared to other
Vincas (Kruczynski et al, 1998b; Lobert et al, 1998).
Our results suggest that vinﬂunine treatment of P388 leukaemia
cells initiates a series of events leading to apoptosis, including DNA
fragmentation accompanied by cellular morphological changes
speciﬁc for apoptosis observed by electron microscopy and forma-
tion of apoptotic bodies containing genetic materials identiﬁed
using a Giemsa-based staining technique (data not shown). Caspase
activation and subsequent cleavage of functionally-essential key
enzymes also play a central role in the biological processing of
apoptosis (Miller, 1997). Caspase-3, required for DNA fragmenta-
tion and for some of the typical morphological changes
associated with apoptosis (Ja ¨nicke et al, 1998), cleaves several
important cellular targets including PARP (Kaufmann et al,
1993). The results presented here show that vinﬂunine treatment
of P388 cells stimulated caspases-3/7 activities and resulted in
PARP degradation in a dose- and time-dependent manner.
Furthermore, Ac-DEVD-CHO, a caspases 3/7 inhibitor inhibited
vinﬂunine-induced DEVD-speciﬁc caspase activity and apoptosis.
Therefore, overall these data suggest that vinﬂunine triggers apop-
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ã 2002 The Cancer Research Campaign British Journal of Cancer (2002) 86(1), 143–150totic mechanisms involving caspases-3/7 in these P388 leukaemia
cells. Involvement of caspases from the caspase-3-like family, as
well as PARP cleavage in drug-induced apoptosis has been demon-
strated previously for several other microtubule damaging agents,
including cryptophycin (Mooberry et al, 1997), taxol, vinblastine,
vincristine (Srivastava et al, 1998) and vinorelbine (Toh et al,
1998).
A great deal of evidence implicates JNKs signalling in apoptosis
occurring in response to diverse cellular stress stimuli, although it
probably has a multifunctional role, varying with the stimulus, the
cell type, the duration of enzyme activation, or the speciﬁc JNKs
isoform(s) involved (Stone and Chambers, 2000). This study
reveals that vinﬂunine induced a dose-dependent JNK1 activation
in P388 leukaemia cells. Earlier reports showed that several struc-
turally-distinct anticancer compounds, including vinblastine,
doxorubicin and etoposide activated JNKs in human KB-3 carcino-
ma cells (Osborn and Chambers, 1996). Subsequently conﬁrmation
of JNKs activation by vincristine, vinblastine, taxol and colchicine
in a variety of cell lines, suggested that this may represent a general
stress response to microtubule dysfunction (Wang et al, 1998;
Stone and Chambers, 2000). Our data showing that JNK1 activa-
tion is associated with vinﬂunine-induced cell death in P388
cells, support these reports.
Mechanisms of drug-induced cell death though appear to be
multiple and context-dependent. Thus, vinﬂunine may trigger
other cell death mechanisms under differing experimental condi-
tions. For example, it was suggested (Torres and Horwitz, 1998)
that taxol-induced cell killing may result from two mechanisms,
involving different mediators depending on the concentration used.
A more general review of cell death mechanisms mediated by
microtubule damaging agents supports the concept that these are
complex processes involving many protein kinase pathways (Wang
et al, 1999b). The Bcl-2 gene family has been shown to play a
crucial role and among multiple genes involved in the regulation
of programmed cell death, this gene family stands out for its ability
to block apoptosis (Hockenbery et al, 1990). Several studies have
associated the disorganization of microtubule structure by drugs
with mitotic arresting- and apoptosis-inducing activities such as
taxol, taxotere, vinblastine, vincristine or the dolastatins with Bcl-
2 phosphorylation in various human tumour cell lines (Haldar et
al, 1997). Bcl-2 can be phosphorylated at serine residues 70 and
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Figure 7 Western blot analyses of the basal levels of Bcl-2 and Bﬂ-1/A1 in cellular extracts of sensitive P388 or vinﬂunine-resistant P388/VFL cells (A).
Quantiﬁcation of the Western blot analyses of the levels of Bcl-2 , Bax, Bﬂ1/A1 and Bcl-xL, performed using a MolecularImager (B).
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1998). Whilst our data revealed no Bcl-2 modiﬁcations in these
murine P388 leukaemia cells after exposure to either vinﬂunine
or to taxol, similar treatments of human CEM leukaemia cells
clearly resulted in Bcl-2 phosphorylation, suggesting that the apop-
totic signal triggered by vinﬂunine in these P388 cells is not
mediated via Bcl-2 phosphorylation. Furthermore, the capacity of
microtubule-interacting agents to cause Bcl-2 phosphorylation
appears to depend more speciﬁcally, on its loop domain status.
The integrity of both ser-70 and ser-87 residues within the loop
domain is necessary for microtubule targeting drug-induced Bcl-2
phosphorylation (Basu and Haldar, 1998). In addition, no phos-
phorylation of Bcl-xL, another anti-apoptotic factor, was detected
in P388 cells exposed to vinﬂunine (data not shown).
Although the relative contribution of apoptosis to drug- and
radiation-induced cell killing remains controversial, there are
examples in the literature indicating that apoptosis clearly contri-
butes to the overall sensitivity of cells to chemotherapeutic agents
(Lowe et al, 1994; Rupnow et al, 1998), especially for haematologi-
cal malignancies, where apoptosis appears to be the dominant form
of cell death after anticancer drug exposure (Brown and Wouters,
1999). To assess whether apoptosis contributes to the sensitivity of
P388 leukaemia cells to vinﬂunine, PARP cleavage and DNA frag-
mentation were studied in sensitive P388 and vinﬂunine-resistant
P388/VFL cells concurrently. The concentration of vinﬂunine
required to induce PARP degradation and DNA fragmentation in
the P388/VFL cells, with a 17-fold level of resistance to vinﬂunine,
was 10-fold higher than that required to induce the same effects in
sensitive cells within the same time frame. This resistance to apop-
tosis induction may of course be mediated by the drug-efﬂux
protein P-gp, which is overexpressed in these P388/VFL cells and
is one mechanism that tumour cells use to escape death induced
by chemotherapeutic agents (Germann, 1996). However, our data
also identiﬁed modiﬁcations at the levels of proteins involved in
apoptosis regulation, namely the Bcl-2 family members. A higher
level of Bcl-2, coupled with an absence of any modiﬁcation of
the expression of the pro-apoptotic factor Bax, was found in
vinﬂunine-resistant P388 cells, associating a high Bcl-2/Bax ratio
with vinﬂunine resistance. These data are consistent with reports
of high Bcl-2/Bax ratios being associated with drug resistance, as
discussed in a recent review (Fujita and Tsuruo, 2000) although
any predictive value of the Bcl-2/Bax ratio in terms of clinical
studies remains to be demonstrated (Stoetzer et al, 1999). In addi-
tion, P388/VFL resistant cells exhibited a higher relative level of
Bﬂ-1/A1 expression, another Bcl-2 family anti-apoptotic member
(Zhang et al, 2000), which appears to play a role in the apoptotic
response of tumour cells to chemotherapy, having been shown to
inhibit etoposide-induced apoptosis (Wang et al, 1999a). Further-
more, expression of Bﬂ-1/A1 in NF-kappaB deﬁcient cells
provided protection against etoposide and cisplatin treatment
(Cheng et al, 2000). Our data indirectly implicate Bcl-2 and Bﬂ-
1/A1 in vinﬂunine-induced cell death mechanisms.
In summary, our data indicate that vinﬂunine induces apoptosis
in murine P388 leukaemia cells, as judged by DNA fragmentation
and PARP cleavage. These apoptosis mechanisms involve caspases-
3/7 and JNK1 activation, but do not require Bcl-2 phosphorylation.
Furthermore, vinﬂunine resistance in P388/VFL cells is associated
with a loss of vinﬂunine’s capacity to induce PARP degradation
and DNA fragmentation and with elevated levels of Bcl-2 and
Bﬂ-1/A1. Overall these results complement and extend our
previously published data (Etie ￿vant et al, 1998; Kruczynski et al,
1998a,b; Hill et al, 1999), providing an interesting preclinical
proﬁle for vinﬂunine which is currently undergoing phase II clin-
ical testing.
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